medigraphic.com
Instituto Nacional de Salud Pública

2022, Number 4

<< Back Next >>

salud publica mex 2022; 64 (4)

Cost-effectiveness analysis of pulse oximetry as a screening test for critical congenital heart defects in Mexico

García-Benítez LA, Granados-García V, Agudelo-Botero M, Mier-Martínez M, Palacios-Macedo A, Durán-Arenas L

Language: Spanish
References: 33
Page: 377-384
PDF size: 295.98 Kb.


ABSTRACT

Objective. To carry out a cost-effectiveness analysis of pulse oximetry as a newborn screening test for critical congenital heart defects (CCHD) in Mexico. Materials and methods. Economic evaluation study was conducted from the perspective of the health care provider. A decision tree model was used to compare between physical examination alone and pulse oximetry screening (POS) as an additional test to physical examination. Results. For every 10 000 newborns, the alternative with POS detected an additional 32 cases of CCHD, with an incremental cost-effectiveness ratio of USD 1 219, and at a willingness-to-pay threshold of USD 25 000 for each early detection, the probability of cost-effectiveness is more than 90%. Conclusion. The cost-effectiveness of POS, as a newborn screening for CCHD, is higher in Mexico than in high-income countries, and represents a cost-effective investment to gain years of life in the child population of Mexico.


REFERENCES

  1. GBD 2017 Congenital Heart Disease Collaborators. Global, regional,and national burden of congenital heart disease, 1990-2017: a systematicanalysis for the Global Burden of Disease Study 2017. Lancet ChildAdolesc Health. 2020;4(3):185-200. https://doi.org/10.1016/S2352-4642(19)30402-X

  2. Jenkins KJ, Castañeda AR, Cherian KM, Couser CA, Dale EK, GauvreauK, et al. Reducing mortality and infections after congenital heart surgeryin the developing world. Pediatrics. 2014;134(5):e1422-e1430. https://doi.org/10.1542/peds.2014-0356

  3. Bastero P, Staveski SL, Zheleva B, Scanlan E, Cabrera AG, Araujo A, et al.Partnership models for the establishment of sustainable paediatric cardiacsurgical and cardiac intensive care programmes in low-and middle-incomecountries. Cardiol Young. 2017;27(S6):S55-S60. https://doi.org/10.1017/S1047951117002621

  4. Secretaría de Salud de México. CubosDinamicos.gob.mx. México:Secretaria de Salud de México/Dirección General en Información en Salud(DGIS), 2020 [citado abril 10, 2022]. Disponible en: http://www.dgis.salud.gob.mx/contenidos/basesdedatos/BD_Cubos_gobmx.html

  5. Van Der Linde D, Konings EE, Slager MA, Witsenburg M, HelbingWA, Takkenberg JJ, et al. Birth prevalence of congenital heart diseaseworldwide: A systematic review and meta-analysis. J Am Coll Cardiol.2011;58(21):2241-7. https://doi.org/10.1016/j.jacc.2011.08.025

  6. Plana MN, Zamora J, Suresh G, Fernandez-Pineda L, ThangaratinamS, Ewer AK. Pulse oximetry screening for critical congenital heartdefects. Cochrane Database Syst Rev. 2018;3(3):CD011912. https://doi.org/10.1002/14651858.CD011912.pub2

  7. Aranguren HC, Londoño D, Troncoso GA, Dominguez MT, Taborda A,Fonseca A, et al. Oximetry and neonatal examination for the detection ofcritical congenital heart disease: a systematic review and meta-analysis.F1000Res. 2019;8:242. https://doi.org/10.12688/f1000research.17989.1

  8. Mahle WT, Newburger JW, Matherne GP, Smith FC, Hoke TR, KoppelR, et al. Role of pulse oximetry in examining newborns for congenitalheart disease: a scientific statement from the AHA and AAP. Pediatrics.2009;124(2):823-36. https://doi.org/10.1542/peds.2009-1397

  9. Bakker MK, Bergman JE, Krikov S, Amar E, Cocchi G, Cragan J, et al.Prenatal diagnosis and prevalence of critical congenital heart defects: aninternational retrospective cohort study. BMJ Open. 2019;9(7):e028139.https://doi.org/10.1136/bmjopen-2018-028139

  10. Eckersley L, Sadler L, Parry E, Finucane K, Gentles TL. Timing of diagnosisaffects mortality in critical congenital heart disease. Arch Dis Child.2016;101(6):516-20. https://doi.org/10.1136/archdischild-2014-307691

  11. Peterson C, Ailes E, Riehle-Colarusso T, Oster ME, Olney RS, CassellCH, et al. Late detection of critical congenital heart disease among usinfants stimation of the potential impact of proposed universal screeningusing pulse oximetry. JAMA Pediatr. 2014;168(4):361-70. https://doi.org/10.1001/jamapediatrics.2013.4779

  12. Granelli A, Meberg A, Ojala T, Steensberng J, Oskarsson G, MellanderM. Nordic pulse oximetry screening – implementation status and proposalfor uniform guidelines. Acta Paediatr. 2014;103(11):1136-42. https://doi.org/10.1111/apa.12758

  13. Mikrou P, Singh A, Ewer AK. Pulse oximetry screening for criticalcongenital heart defects: a repeat UK national survey. Arch Dis ChildFetal Neonatal Ed. 2017;102(6):F558. https://doi.org/10.1136/archdischild-2017-313378

  14. Mahle WT, Martin GR, Beekman RH, Morrow WR, Section on Cardiologyand Cardiac Surgery Executive Committee. Endorsement of healthand human services recommendation for pulse oximetry screening forcritical congenital heart disease. Pediatrics. 2012;129(1):190-2. https://doi.org/10.1542/peds.2011-3211

  15. Martin GR, Ewer AK, Gaviglio AML, Hom LA, Saarinen AM, SontagMP, et al. Updated strategies for pulse oximetry screening for criticalcongenital heart disease. Pediatrics. 2020;146(1):e20191650. https://doi.org/10.1542/peds.2019-1650

  16. Diario Oficial de la Federación. DECRETO por el que se adicionauna fracción II Bis al artículo 61 de la Ley General de Salud. Secretaria deGobernación [internet]. Ciudad de México: DOF, 2021 [citado abril 10,2022]. Disponible en: http://www.dof.gob.mx/nota_detalle.php?codigo=5619922&fecha=01/06/2021

  17. Sola A, Rodríguez S, Young A, Varela LL, Villamayor RM, Cardetti M, etal. CCHD screening implementation efforts in Latin American countriesby the Ibero American Society of Neonatology (SIBEN). Int J NeonatalScreen. 2020:6(1):21. https://doi.org/10.3390/ijns6010021

  18. Thangaratinam S, Brown K, Zamora J, Khan KS, Ewer AK. Pulseoximetry screening for critical congenital heart defects in asymptomaticnewborn babies: a systematic review and meta-analysis. Lancet.2012;379(9835):2459-64. https://doi.org/10.1016/S0140-6736(12)60107-X

  19. Ewer AK, Deshpande SA, Gale C, Stenson BJ, Upton M, Evans C, etal. Potential benefits and harms of universal newborn pulse oximetryscreening: response to the UK National Screening Committee publicconsultation. Arch Dis Child. 2020;105(11):1128-9. https://doi.org/10.1136/archdischild-2019-317859

  20. Roberts TE, Barton PM, Auguste PE, Middleton LJ, Furmston AT,Ewer AK. Pulse oximetry as a screening test for congenital heartdefects in newborn infants: a cost-effectiveness analysis. Arch Dis Child.2012;97(3):221-6. https://doi.org/10.1136/archdischild-2011-300564

  21. Peterson C, Grosse SD, Oster ME, Olney RS, Cassell CH. Costeffectivenessof routine screening for critical congenital heart disease inUS newborns. Pediatrics. 2013;132(3):e595-e603. https://doi.org/10.1542/peds.2013-0332

  22. Griebsch I, Knowles RL, Brown J, Bull C, Wren C, Dezateux CA. Comparingthe clinical and economic effects of clinical examination, pulse oximetry,and echocardiography in newborn screening for congenital heartdefects: a probabilistic cost-effectiveness model and value of informationanalysis. Int J Technol Assess Health Care. 2007;23(2):192-204. https://doi.org/10.1017/S0266462307070304

  23. Diario Oficial de la Federación. Norma Oficial Mexicana NOM-007-SSA2-2016, Para la atención de la mujer durante el embarazo, parto ypuerperio, y de la persona recién nacida. Ciudad de México: DOF, 2016[citado abril 10, 2022]. Disponible en: http://dof.gob.mx/nota_detalle.php?codigo=5432289&fecha=07/04/2016

  24. Ewer AK, Furmston AT, Middleton LJ, Deeks J, Daniels J, Pattison H,et al. Pulse oximetry as a screening test for congenital heart defects innewborn infants: a test accuracy study with evaluation of acceptability andcost-effectiveness. Health Technol Assess. 2012;16(2):1-184. https://doi.org/10.3310/hta16020

  25. Mier-Martínez M, García-Benítez L, Santiago-Vázquez V. Tamiz cardiológiconeonatal en México. Estudio multicéntrico. En: VI Congreso Nacionalde la Asociación Mexicana de Especialistas en Cardiopatías Congénitas(AMECC2021); 2021 jun 10-12; Los Cabos (BCS), México.

  26. WHO Commission on Macroeconomics and Health & World HealthOrganization. Macroeconomía y salud: invertir en salud en pro deldesarrollo económico: informe de la Comisión sobre Macroeconomía ySalud. Sinopsis. Ginebra: OMS, 2001 [citado abril 10, 2022]. Disponible en:https://apps.who.int/iris/handle/10665/42465

  27. Hoke TR, Donohue PK, Bawa PK, Mitchell RD, Pathak A, Rowe PC,et al. Oxygen saturation as a screening test for critical congenital heartdisease: a preliminary study. Pediatr Cardiol. 2002;23(4):403-9. https://doi.org/10.1007/s00246-002-1482-8

  28. Knowles R, Griebsch I, Dezateux C, Brown J, Bull C, Wren C. Newbornscreening for congenital heart defects: a systematic review and costeffectivenessanalysis. Health Technol Assess. 2005;9(44):1-152. https://doi.org/10.3310/hta9440

  29. González-Andrade F. High altitude as a cause of congenital heartdefects: a medical hypothesis rediscovered in Ecuador. High Alt Med Biol.2020;21(2):126-34. https://doi.org/10.1089/ham.2019.0110

  30. Reeder MR, Kim J, Nance A, Krikov S, Feldkamp ML, Randall H, et al.Evaluating cost and resource use associated with pulse oximetry screeningfor critical congenital heart disease: empiric estimates and sourcesof variation. Birth Defects Res A Clin Mol Teratol. 2015;103(11):962-71.https://doi.org/10.1002/bdra.23414

  31. Peterson C, Dawson A, Grosse S, Riehle-Colarusso T, Olney R, TannerJ, et al. Hospitalizations, costs, and mortality among infants with criticalcongenital heart disease: how important is timely detection? Birth DefectsRes A Clin Mol Teratol. 2013;97(10):664-72. https://doi.org/10.1002/bdra.23165

  32. Kochilas LK, Lohr JL, Bruhn E, Borman-Shoap E, Gams BL, PylipowM, et al. Implementation of critical congenital heart disease screening inMinnesota. Pediatrics. 2013;132(3):e587-e594. https://doi.org/10.1542/peds.2013-0803

  33. Woods B, Revill P, Sculpher M, Claxton K. Country-level cost-effectivenessthresholds: initial estimates and the need for further research. ValueHealth. 2016;19(8):929-35. https://doi.org/10.1016/j.jval.2016.02.017




2020     |     www.medigraphic.com